Login / Signup

Pan-pox-specific T-cell responses in HIV-1-infected individuals after JYNNEOS vaccination.

Marta Sisteré-OróJuan DuDiana D J WortmannMarina D FilippiEsperanza Cañas-RuanoItziar Arrieta-AldeaAgustín Marcos-BlancoXavier CastellsSantiago GrauNatalia García-GiraltDaniel Perez-ZsoltRytis BoreikaNuria Izquierdo-UserosRoberto Güerri-FernandezAndreas Meyerhans
Published in: Journal of medical virology (2023)
People living with human immunodeficiency virus (HIV) are the individuals most affected by the current Monkeypox virus outbreak that was first announced in May 2022. Here we report Pan-pox-specific T-cell responses in a cohort of HIV-1-infected individuals after receiving the nonreplicative, attenuated smallpox vaccine JYNNEOS from Bavarian Nordic. Intradermal (i.d.) and subcutaneous (s.c.) vaccination was safe without major side effects. Dose-sparing i.d. vaccination was superior to s.c. vaccination and promoted T-cell polyfunctionality, and the expression of the gut-homing marker α4β7 integrin on lymphocytes. HIV-1-infected individuals with CD4 T-cell counts ≤500/mm 3 blood required at least a booster vaccination to exhibit efficient virus-specific T-cell responses. The magnitude of the Th1 response after this booster directly correlated with the CD4 T-cell count of the vaccinees. Further studies with a larger number of participants are warranted to confirm and expand our observations.
Keyphrases
  • hiv infected
  • antiretroviral therapy
  • human immunodeficiency virus
  • hiv positive
  • hiv aids
  • peripheral blood
  • hepatitis c virus
  • minimally invasive